ClinicalTrials.gg
TerminatedNCT02669030Updated Nov 4, 2026

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

A Phase 4 interventional study of suvorexant and Placebo in Depression, Major Depressive Disorder and MDD, sponsored by Institute for Advanced Medical Research, Alpharetta, GA. Terminated at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institute for Advanced Medical Research, Alpharetta, GA · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
inability to recruit volunteers

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.
Updated Nov 4, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Enrollment
2,402nd of 3,322
32 · median 72
Started
2017
with 140 others
Phase 4
265 of 3,715
19 open now
Registered
1,662nd of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 2,402nd largest by enrollment of the 3,322 interventional ones that give a count, is one of 141 that started in 2017, is one of 265 in phase 4, and was the 1,662nd registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

574 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

Depression with ongoing insomnia is a common clinical presentation with patients. Clinical data suggests that patients with insomnia that receive concomitant treatment with a sleep aid experience a more robust antidepressant response along with a quicker response. The purpose of this clinical study is to compare the effectiveness of the FDA-approved insomnia medication suvorexant, also known as Belsomra®, as add-on treatment to an antidepressant to that of placebo plus antidepressant treatment in patients with depression and residual or ongoing insomnia.

Read the detailed description

Many patients with depression suffer from residual insomnia. This study is a six week, randomized, double-blind, placebo-controlled, trial to study suvorexant augmentation of continuing antidepressant therapy against placebo with continuing antidepressant therapy. Patient volunteers must be on a stable antidepressant treatment and will remain on this treatment for the duration of the study. Patient volunteers that qualify and enroll in the clinical trial will either receive suvorexant 10 mg/day and may have it adjusted to a dose of either 15 mg or 20 mg/day. Treatment is for a total of six weeks in addition to a clinical follow-up visit.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written
  • Diagnosis of depression (MDD)
  • Currently on antidepressant
  • Healthy and/or stable medically

Exclusion criteria

Exclusion Criteria:

  • unwilling to discontinue current use of sedative hypnotics/sleep aids/benzodiazepines or over the counter sleep aids/supplements
  • currently using other psychotropics other than antidepressants
  • at risk of self harm or a suicide attempt within the past 12 months
  • history or presence of psychotic disorders
  • known to suvorexant
  • presence of any other sleep disorder other than residual insomnia of depression
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Suvorexant

    suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment

    Drug: suvorexant

  • Placebo comparator
    Placebo

    no augmentation of FDA-approved antidepressant treatment

    Drug: Placebo

Interventions

  • an FDA-approved sleep aid

    Also known as: Belsomra®

  • DrugPlacebo

    control group

06

What researchers measure

Primary outcomes

  1. Total Sleep Time

    assessment of total amount of time spent sleeping

    Time frame: Six weeks ( baseline to end of treatment)

Secondary outcomes

  1. Insomnia Severity Index (ISI)

    assessment of insomnia severity

    Time frame: Six weeks ( baseline to end of treatment)

  2. Hamilton Depression Rating Scale

    assessment fo depressive symptom severity

    Time frame: Six weeks ( baseline to end of treatment)

  3. Sheehan Disability Scale

    assessment of impact of symptoms on performance

    Time frame: Six weeks ( baseline to end of treatment)

  4. Wake After Sleep Onset (WASO)

    assessment of amount of time spent awake after initial onset of sleep

    Time frame: Six weeks ( baseline to end of treatment)

  5. Sleep Latency (SL)

    assessment of amount of time it takes to fall asleep

    Time frame: Six weeks ( baseline to end of treatment)

  6. Perceived Deficits Questionnaire (PDQ)

    a brief patient-rated scale to assess subjective cognitive dysfunction in people with depression

    Time frame: Six weeks ( baseline to end of treatment)

07

Study locations

2 sites
  • Institute for Advanced Medical Research @ Mercer Univeristy
    Atlanta, Georgia 30341, United States
  • Medical College of GA at Augusta Univeristy
    Augusta, Georgia 30912, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2017 to primary completion in Feb 2019, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Dec 2019 → Feb 2019 and completion Dec 2019 → Feb 2019.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2016
First posted
Jan 29, 2016
StartActual
Mar 1, 2017
Primary completionActual
Feb 26, 2019was Dec 2019
CompletionActual
Feb 26, 2019was Dec 2019
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated inability to recruit volunteers
changed Nov 4, 2026
Primary completion
Dec 2019→Feb 26, 2019 (actual)
Nov 4, 2026
Study completion
Dec 2019→Feb 26, 2019 (actual)
Nov 4, 2026
Enrollment
74 (estimated)→32 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Status unknown→Terminated
    Why stopped inability to recruit volunteers
    Primary completion Dec 2019→Feb 26, 2019 (now actual)
    Study completion Dec 2019→Feb 26, 2019 (now actual)
    Enrollment 74 (estimated)→32 (actual)
    + 4 other changes: design details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02669030
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Collaborators
Augusta University, Dept. of Psychiatry
Responsible party
Sponsor
First posted
Jan 29, 2016
Start date
Mar 1, 2017
Primary completion
Feb 26, 2019
Completion
Feb 26, 2019
Last update
Nov 4, 2026

Study contacts

Angelo Sambunaris, MD
principal investigator · Institute for Advanced Medical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suvorexant

Start the discussion